TSHA · Taysha Gene Therapies, Inc.
$5.95
-0.04 (-0.67%)
At close · Aug 14
Market Cap
$1.94B
Shares
325.83M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-11 | — | |
| 10-Q | 2026-08-11 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-25 | 2026-06-24 | |
| 8-K | 2026-06-22 | — | |
| 8-K | 2026-06-02 | 2026-06-01 | |
| 8-K | 2026-05-06 | — | |
| 10-Q | 2026-05-06 | 2026-03-31 | |
| DEF 14A | 2026-04-22 | 2026-06-01 | |
| Investor Event Transcript | 2026-03-31 | — | |
| 10-K | 2026-03-19 | 2025-12-31 | |
| 8-K | 2026-03-19 | — | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-11-04 | — | |
| 8-K | 2025-10-16 | — | |
| 8-K | 2025-10-09 | — | |
| 8-K | 2025-10-02 | — | |
| 8-K | 2025-08-12 | — | |
| 10-Q | 2025-08-12 | 2025-06-30 | |
| 8-K | 2025-06-03 | 2025-06-02 | |
| 8-K | 2025-05-29 | 2025-05-28 | |
| 8-K/A | 2025-05-29 | 2025-05-28 | |
| 8-K | 2025-05-28 | — | |
| 10-Q | 2025-05-15 | 2025-03-31 | |
| 8-K | 2025-05-15 | — | |
| DEF 14A | 2025-04-21 | 2025-06-02 | |
| 10-K | 2025-02-26 | 2024-12-31 | |
| 8-K | 2025-02-26 | — | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 10-Q | 2024-08-12 | 2024-06-30 | |
| 8-K | 2024-08-12 | — | |
| 8-K | 2024-06-26 | 2024-06-25 | |
| 8-K | 2024-06-26 | — | |
| 8-K | 2024-06-18 | — | |
| 8-K | 2024-05-30 | 2024-05-29 | |
| 10-Q | 2024-05-14 | 2024-03-31 | |
| 8-K | 2024-05-14 | — | |
| DEF 14A | 2024-04-18 | 2024-05-29 | |
| 8-K | 2024-03-19 | — | |
| 10-K | 2024-03-19 | 2023-12-31 | |
| 8-K | 2024-01-10 | — | |
| 8-K | 2023-12-20 | 2023-12-14 | |
| 8-K | 2023-11-15 | — | |
| 10-Q | 2023-11-14 | 2023-09-30 | |
| 8-K | 2023-11-14 | — | |
| 8-K | 2023-11-01 | 2023-10-30 | |
| DEF 14A | 2023-10-05 | 2023-11-15 | |
| 8-K | 2023-09-26 | — |
Showing 1–50 of 125 filings
Key facts
CIK
1806310
CUSIP
877619106
13F (30d)
208 filings
202 filers
Visit website
Investor relations